Abstract

Since the discovery of bioactive molecules sequestered in dentine, researchers have been exploring ways to harness their activities for dental regeneration. One specific area, discussed in this review, is that of dental-pulp capping. Dental-pulp caps are placed when the dental pulp is exposed due to decay or trauma in an attempt to enhance tertiary dentine deposition. Several materials are used for dental-pulp capping; however, natural biomimetic scaffolds may offer advantages over manufactured materials such as improved aesthetic, biocompatibility and success rate. The present review discusses and appraises the current evidence surrounding biomimetic dental-pulp capping, with a focus on bioactive molecules sequestered in dentine. Molecules covered most extensively in the literature include transforming growth factors (TGF-βs, specifically TGF-β1) and bone morphogenetic proteins (BMPs, specifically BMP-2 and BMP-7). Further studies would need to explore the synergistic use of multiple peptides together with the development of a tailored scaffold carrier. The roles of some of the molecules identified in dentine need to be explored before they can be considered as potential bioactive molecules in a biomimetic scaffold for dental-pulp capping. Future in vivo work needs to consider the inflammatory environment of the dental pulp in pulpal exposures and compare pulp-capping materials.

Keywords: Dental pulp, pulp capping, pulp regeneration, biologics, biomaterials, growth factors, dentistry, dentinogenesis, regenerative medicine, biomaterials.

*Address for correspondence: School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, UK
Email: g.feichtinger@leeds.ac.uk

Copyright policy: This article is distributed in accordance with Creative Commons Attribution Licence (http://creativecommons.org/licenses/by-sa/4.0/).
PIGF  placental growth factor  
SCF   stem cell factor  
SIBLING small integrin-binding ligand, N-linked glycoprotein  
SLRP s small leucine-rich proteoglycans  
SPARC secreted protein, acidic and rich in cysteine  
TGF transforming growth factor  
VEGF vascular endothelial growth factor  
WNT wingless/integrated

Introduction

Caries (dental decay) is the most prevalent non-communicable human disease and is linked to “a low quality of life” (Åkesson et al., 2016). The Global Burden of Disease Study estimated that 3.58 billion people worldwide have untreated caries (Web ref. 1). Indirect costs (for example, work absences) due to caries worldwide amount to a loss of 144 billion USD/year (Listl et al., 2015), highlighting the significant impact caries have at a global level.

The crowns of teeth are made of enamel, dentine and pulp. Dentine is a living structure, with an inorganic content similar to bone, being predominantly hydroxyapatite, calcium and phosphate salts (Sloan, 2015). The dental pulp, which is encased by dentine, contains vessels, nerves and cells that maintain the vitality of the tooth. Dentine and pulp are inextricably linked (termed together as DPC). They share embryological origin [both derive from the ectomesenchyme (Zohrabian et al., 2015)] and both release factors acting on the other (Smith, 2003), facilitating a state of homeostasis and, when necessary, regeneration and repair. The DPC is the only part of the tooth with in vivo regenerative potential and is being increasingly studied for its potential in biological-scaffold production (Hashemi-Beni et al., 2017; Qu et al., 2015) and dental-tissue regeneration.

Dentineogenesis is the production of dentine and, in a healthy body, it is performed by odontoblasts (dentine-producing cells). Odontoblasts are largely inactive after primary dentineogenesis (Table 1). However, following insult to the pulp, odontoblasts play a role in wound healing in the form of reactionary dentineogenesis, where they lay down dentine to seal the vital pulp from the insult. Should the stimulus be great enough to kill the odontoblasts (such as a significant trauma or deep caries), DPSCs will migrate to the site of injury, differentiate into odontoblast-like cells and begin laying down dentine, a process called reparative dentineogenesis. This results in a dentine bridge, sealing the precious pulp from further insults (McLachlan et al., 2003).

Tertiary dentineogenesis is driven by a dental injury, although the interplay between inflammation and regeneration is a delicate balance. Typically, exposed dental pulps are inflamed and often infected. It is generally accepted that only when infection and inflammation are under control will reparative actions occur in the dental pulp (Cooper et al., 2014). Many of the cytokines and growth factors involved in tertiary dentineogenesis, at high doses, may lead to pulpal death and prevent DPSC differentiation (Cooper et al., 2014). However, certain inflammatory cells (such as macrophages and dendritic cells) have also been shown to stimulate odontoblast differentiation (Goldberg et al., 2008a; Saito et al., 2011). Similarly, molecules upregulated in caries, such as C5a and stromal cell-derived factor 1/CXCL12, can recruit immune cells as well as DPSCs (Cooper et al., 2014). These studies highlight the intricate, delicate and vital interplay between inflammation and regeneration in tertiary dentineogenesis and caries.

Reparative dentineogenesis is a complex process, as DPSCs need to be recruited to the site of injury, undergo differentiation and deposit dentine. Understandably, this is more time-consuming than reactionary dentineogenesis and, because of this, it is often ineffective at sealing the pulp from the insult. Significantly, this process is driven by the release of bioactive molecules (including growth factors, cytokines and other matrix molecules) sequestered within dentine during primary dentineogenesis and released following dentine damage. These molecules can stimulate reparative and reactionary dentineogenesis (Smith et al., 2012) and are summarised in Fig. 1.

When a pulp is exposed because of a trauma, mechanical action (typically iatrogenic) or caries, the clinician has the choice of either attempting to save the pulp (through a direct pulp cap) or not [leading to a root canal treatment (endodontics) or an extraction]. PCAs attempt to seal the pulp by encouraging tertiary dentine deposition. Direct pulp caps can be technically challenging to perform successfully and correctly, with Bjørndal et al. (2017) reporting success rates as low as 9% after pulp exposures in a 5-year follow-up. When the pulp is exposed, the tooth needs to be isolated (ideally with a rubber dam), any further caries removed, the area cleaned/wound lavage, haemostasis achieved, the PCA prepared/mixed, placed and allowed to set (if required) and the cavity restored. Clinicians may also decide to remove some of the superficial pulp that has been exposed (termed as partial pulpotomy), in an attempt to remove any inflamed pulpal tissue that may impair healing (Bjørndal et al., 2019). Besides the PCA used, numerous other factors may influence the success rates of a pulp cap, such as:

- bacterial microleakage from the restoration, operative debris from the cavity preparation, uncontrolled haemorrhage (Murray et al., 2002),
- experience of the operator, type of cavity (interdental/occlusal) (Ritter, 2007),
- time to permanent restoration (Mente et al., 2014),
- type of exposure (carious/mechanical/trauma) (Ritter, 2007),
- type of lavage/haemostasis agent used (Tüzün et al., 2012).
Table 1. Comparison of primary, secondary and tertiary dentine.

<table>
<thead>
<tr>
<th>Dentine type</th>
<th>When/where present</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary</td>
<td>Deposited at a slow rate throughout life after primary dentinogenesis by odontoblasts.</td>
</tr>
<tr>
<td>Secondary</td>
<td>Reactionary: formed following mild/&quot;slow and chronic&quot; insult to the pulp. Formed by odontoblasts. Tubular structure, similar to primary dentine.</td>
</tr>
<tr>
<td>Tertiary</td>
<td>Reparative: formed following significant insult to the pulp, resulting in odontoblast death. Formed by odontoblast-like cells derived from resident DPSCs. Atubular structure, often showing some similarities to bone.</td>
</tr>
</tbody>
</table>

A pulp cap is deemed successful if at 75-90 d a dentine bridge has formed and the tooth remains vital (Stanley and Pameijer, 1997), although typically a dentine bridge begins to form within 30 d of the original pulp cap and is largely completed by 130 d (Hargreaves and Cohen, 2010). No PCAs currently available are perfect and, considering the prevalence of caries, it is imperative that cost-effective materials with high success rates, desirable clinical outcomes and suitable handling qualities are available for clinical use. Furthermore, evidence supporting the use of many PCAs is generally lacking, with poor quality clinical studies often including sound teeth, limited follow-up time, lack of histological data, young healthy patients and tooth isolation (Hilton, 2009), which often make comparison to real-life clinical work challenging.

Pulp-capping materials

There are many pulp-capping materials/agents available commercially, with Ca(OH)\(_2\) and Ca\(_3\)SiO\(_4\)-based materials (MTA and other Ca\(_3\)SiO\(_4\)-based cements) being the most used in clinical practice.

Of the more commonly used PCAs, Ca(OH)\(_2\) has been used the longest (having been first explored in the 1920s) and for many years has been considered the gold standard for a direct pulp cap (Hilton, 2009; Qureshi et al., 2014). Ca(OH)\(_2\) is often considered as the benchmark to compare newer PCAs against – *in vivo* and *in vitro* – and there is a wealth of literature supporting its use. The high alkalinity of Ca(OH)\(_2\) eliminates micro-organisms, providing a favourable environment for dentineogenesis. However, this has negative implications too, making Ca(OH)\(_2\) cytotoxic, resulting in further pulpal necrosis (Youssef et al., 2020). The exact process of dentineogenesis in a Ca(OH)\(_2\) pulp-capped tooth remains contentious, with some studies supporting the notion that irritation, inflammation and necrosis in the pulp caused by Ca(OH)\(_2\) initiate dentineogenesis *via* an unknown pathway and others suggesting that dentineogenesis is due to Ca(OH)\(_2\) facilitating release of bioactive molecules sequestered in dentine (Bjørndal et al., 2019; Graham et al., 2006; Hilton, 2009); or potentially a mixture of the two. Ca(OH)\(_2\) presents numerous issues as a PCA, such as high solubility, lack of adhesion to dentine and ‘tunnel defects’ in the reparative dentine formed (Qureshi et al., 2014).

MTA is newer to the commercial market than Ca(OH)\(_2\), although has been used for pulp capping since the 1990s (Zafar et al., 2020), and is thought to have higher success rates than Ca(OH)\(_2\) (da Rosa et al., 2018b; Paula et al., 2018; Zhu et al., 2015). Moisture is required for MTA to set and, when water is added, a colloidal gel composed of calcium oxide crystals is formed (calcium silicate hydrate) and Ca(OH)\(_2\) is released, imparting much of the MTA’s known antimicrobial activity (Zafar et al., 2020). MTA liberates numerous growth factors from dentine during pulp capping (Tomson et al., 2017). Although MTA would appear to be a good PCA based upon the success rates, there are numerous issues with its use, for example, long setting times (>2 h for some brands), discolouration of teeth, poor handling characteristics (due to its crumbly nature), risk of pulpal obliteration and high cost (Linsuwannont et al., 2017; Qureshi et al., 2014; Zafar et al., 2020). Due to the release of Ca(OH)\(_2\), MTA also has high alkalinity, which again is cytotoxic (Kim et al., 2019; Youssef et al., 2019). More recent modifications of MTA have attempted to remedy some of these problems (*e.g.*, newer generation versions of MTA have faster setting times through the addition of either CaSO\(_4\) or NaOCl, reduction in particle size or addition of substances to allow for light curing) and to reduce tooth discoloration (Zafar et al., 2020), although long-term studies demonstrating no reduction in efficacy are lacking.

Newer Ca\(_3\)SiO\(_4\)-based cements (*e.g.*, BioDentine™ (Septodont, Niederkassel, Germany)) have been explored to overcome numerous issues of previous PCAs (*e.g.*, BioDentine™ has a shorter setting time than MTA and improved handling characteristics (Zafar et al., 2020)) but still problems exist (*e.g.*, tooth discolouration and age-dependent results (Lipski et al., 2018)). Again, due to the high alkalinity of the material, Ca\(_3\)SiO\(_4\)-based cements will have cytotoxic effects on the pulp (Youssef et al., 2019). No statistically significant differences in the various outcomes were found in a systematic review when MTA was compared to Ca\(_3\)SiO\(_4\)-based cements (Paula et al., 2018), although a significant lack of long-term cohort studies and
randomised controlled trials were identified as a significant issue, partly due to the newness of the material.

A lack of a highly effective PCA is the driving motivator behind the exploration of more biomimetic approaches to pulp capping, with the hope of discovering and utilising key factors present during tertiary dentineogenesis to drive DPC regeneration. Many of the bioactive molecules within dentine can be liberated by current PCAs (Tomson et al., 2017) or through chemical treatment of the dentine (Zhao et al., 2000), although this release is poorly controlled in terms of frequency and volume. By applying these molecules extraneously, it may be possible to exploit their actions in a biomimetic pulp-capping agent to actively drive tertiary dentineogenesis, in a controlled manner, for pulp capping, maintaining the vitality of the tooth. These data can be used to inform dentineogenic scaffold design – allowing for the ideal biomimetic environment to be fabricated, which can include the bioactive molecules pertinent for reparative dentineogenesis – and provide an ideal environment for DPSC migration and differentiation, excluding noxious irritants present in many current PCAs and in the inflamed pulp. In essence, harnessing the positive reparative factors of tertiary dentineogenesis and excluding the negative factors that drive pulpal necrosis. Moreover, many of the scaffolds designed to carry bioactive molecules can also carry medicaments such as anti-inflammatories and antimicrobials, which will be of considerable benefit in controlling pulpal inflammation and any residual caries. In addition, many of these scaffolds also swell in the presence of moisture, which may be beneficial in providing a seal from the oral environment. When considering the possibility of a biomimetic PCA, it is important to remember that tertiary dentineogenesis occurs in the pulp and, by creating an environment similar to the dental pulp, it may be possible to speed up the process of reparative dentineogenesis with fewer unwanted side effects. As such, a scaffold loaded with biomimetic bioactive molecules may prove to be an ideal pulp-capping material, fulfilling the key requirements of a PCA, which include: 1) immediate seal of the dental cavity, protecting the pulp as a dentine bridge is forming; 2) biocompatibility and non-cytotoxic; 3) possess of bioactive properties

**Fig. 1.** Schematic diagram summarising the bioactive molecules sequestered in dentine that have been explored in the literature, and the present review, for pulp-capping dentineogenesis. Molecules with the most evidence supporting their use are in green, intermediate evidence in amber and little evidence in grey. Molecules in white have been included for completeness. Interactions are shown by arrows.
capable of triggering the biological mechanisms for dentine-bridge production (Bjørndal et al., 2019).

Bioactive molecules, such as DNA (gene therapy) or proteins for dentinogenic pulp-capping may be added to scaffolds. Gene therapy eliminates the need for externally produced recombinant factors and gene transfection can enhance the efficacy of stem cell applications (Yang et al., 2009). Some bioactive molecules (for example BMPs) have a short half-life and are required in high concentrations at local sites to be effective; therefore, the ability for elevated local production of BMPs by the patient may be advantageous and could be achieved through gene transfection (Nakashima, 1994a; Nakashima and Reddi, 2003).

**Purpose and Scope**

The purpose of the present review was to explore the literature surrounding extracellular bioactive molecules known to be sequestered in dentine (Austah et al., 2019; Goldberg et al., 2011; Schmalz et al., 2017; Smith et al., 2012; Smith et al., 2016; Tomson et al., 2017) and summarise current evidence for their utility as PCAs.

It is pertinent in biomaterial engineering to consider the delivery mechanism (or carrier) when considering delivery of any molecules, because spatiotemporal control over the release of bioactive molecules controls the resulting tissue regeneration (Rambhia and Ma, 2015). However, extensive coverage of carriers for pulp capping is beyond the scope of the present review.

For all molecules discussed, the study focused on literature published in the English language, with a preference for best and most recent evidence for the use of each molecule, namely in vivo studies over in vitro work, where available, and focused on studies specifically addressing pulp capping. However, there is a general lack of large-scale works in this field, with most publications being small-scale singular animal or in vitro studies. Hence, the present review attempted to accumulate the most pertinent works on each molecule and evaluate current evidence for its utility within a PCA.

**Extracellular bioactive molecules known to be sequestered in dentine**

**Anabolic/dentineogenic and mitogenic molecules**

TGF-β

TGF-βs (isoforms TGF-β1, TGF-β2 and TGF-β3) are multifunctional cytokines secreted following an initial inflammatory response, are potent modulators of tissue repair and are expressed by all cells in the human body (Niwa et al., 2018; Vander Ark et al., 2018). TGF-βs at the cellular level regulate proliferation, migration, differentiation as well as apoptosis and, more generally, they play a role in regulation of inflammatory responses and both tumour suppression and progression (Vander Ark et al., 2018). Factors such as pH, integrins and various proteases (e.g. MMP2, MMP9, plasmin) activate TGF-βs (Niwa et al., 2018). TGF-β1, TGF-β2 and TGF-β3 are receptor ligands which bind to TGF-β receptors (TGF-β receptor 1, TGF-β receptor 2 and TGF-β receptor 3) (Vander Ark et al., 2018), with TGF-β1 being the predominant isoform (Niwa et al., 2018). Within pulpal inflammation, TGF-β1 is involved in chemotaxis of inflammatory cells, angiogenesis, deposition of ECM and formation of new tissue (About et al., 2000a). In addition, it plays a role in odontoblast differentiation (Begue-Kirn et al., 1992; Nakashima, 1992). Within the pulp, TGF-β1 is activated through degradation of the TGF-β1 complex, leading to elevated DSPP and MMP20 levels (Niwa et al., 2018). TGF-β1 interacts with the ECM in a unique way. It is secreted as a homodimer, non-covalently attached to LAP. When bound to LAP, TGF-β1 is prevented from attaching to cell receptors [and is therefore latent (TGF-β1-LAP)]. TGF-β1-LAP is bound and stored in the ECM through LTBP-1. Mechanical forces within the ECM (from actin and myosin cellular contractions) are transmitted to a binding site present on LAP, which induces a hypothetical conformational change, liberating the bound TGF-β1. In essence, a pulling mechanism from a cellular-bound integrin releases TGF-β1 from the ECM-bound TGF-β1-LAP. Application of a force to TGF-β1-LAP without a mechanical anchor (provided by the LTBP-1 binding to the ECM) would result in dragging/translocation of the complex and no conformational change facilitating the release of TGF-β1 (Hinz, 2015). This storage and release mechanism from the ECM produces a disjoint between secretion time and action time of TGF-β1 (Hinz, 2015).

There are numerous in vitro studies demonstrating the ability of TGF-β1 for inducing odontogenic differentiation of isolated DPSCs (Begue-Kirn et al., 1992; 1994). However, the present review focused on the potential of bioactive molecules being used as pulp-capping agents and, currently, only one human in vivo study has been performed on this subject (Kunarti, 2008). Therefore, most of the current best evidence for the use of TGF-β1 as a bioactive molecule comes from in vivo animal models. The evidence for use of TGF-βs as a bioactive molecule for pulp capping are discussed below.

In the only in vivo human study, Kunarti (2008) demonstrated that TGF-β1 loaded onto collagen membranes (20 ng/mL, 5 µL) can act as a suitable pulp-capping agent, producing similar effects to Ca(OH)2 but with earlier induction of angiogenesis. However, this study used sound premolars scheduled for extraction due to orthodontic reasons, with a follow up of only 21 d, making the comparison to routine clinical use (i.e. a carious tooth with a long-term restoration) difficult; although, the initial results appeared promising (Kunarti, 2008).
In a dog model, Li et al. (2014) used a chitosan bilayer membrane, containing TGF-β1-loaded chitosan microspheres, and compared the effectiveness of this loaded biomaterial for pulp capping to an unloaded chitosan scaffold, no pulp cap and Ca(OH)₂. They found that all agents and the control group induced an initial inflammatory response, but only the Ca(OH)₂ and loaded chitosan groups produced reparative dentine – and of these, the loaded chitosan scaffold produced 3-6 times more reparative dentine than Ca(OH)₂. In an earlier dog model study by Tziafas et al. (1998), TGF-β1-loaded filters formed odontoblasts and dentine and were more successful than FGF and IGF in producing dentine. Similar findings were also identified by Zhang et al. (2008) using a goat model with TGF-β1 loaded onto poly(lactic-co-glycolic acid) microspheres used for pulp capping. They found that a higher concentration of TGF-β1 (400 ng) formed a better tertiary dentine bridge than a lower concentration (20 ng); none of the negative controls produced dentine (Zhang et al., 2008). Conversely, in a rat study by Oliva-Rodríguez et al. (2011), TGF-β1 loaded onto alginate microparticles, specifically designed for controlled release, produced a similar result to Ca(OH)₂ for pulp capping. However, with the addition of BMP-7 to the TGF-β1-loaded alginate, the effects were improved (Oliva-Rodríguez et al., 2011).

When comparing TGF-β1 to other bioactive molecules, TGF-β1 has been shown to outperform BMP-7 and WNT-1. In a porcine-model study, a Ca₃SiO₃-based material was soaked in a solution containing BMP-7, TGF-β1 or WNT-1 and each bioactive molecule was assessed for pulp capping. Each calcium silicate scaffold was soaked in 30 μL of a 300 mg/mL porcine albumin solution containing 30 mg of the bioactive molecule. TGF-β1 induced odontoblastic differentiation and a more consistent reactive dentine formation of an appropriate depth and structure for effective pulp capping (Tziafas et al., 2017). Hu et al. (1998) also showed that TGF-β1 loaded onto a collagen scaffold can outperform PDGF-BB, FGF, EGF, IGF and Ca(OH)₂ in a rat animal model. In contrast to the studies supporting the use of TGF-β1, Nakashima (1994a) reported no dentine formation and impaired pulp healing with TGF-β1 (2 μg) loaded onto collagen and implanted into a dog model.

Based upon these studies, it is possible that the release frequency and nature of the carrier may have an effect on the activity of TGF-β1 in inducing tertiary dentineogenesis and reparative pulpal changes. However, it is also clear that TGF-β1 may be as good, if not better than Ca(OH)₂, as a PCA. Modification of the delivery mechanism to incorporate synergistic growth factors could be promising for improved results. The wealth of literature supporting TGF-β1 makes it a front-runner for inclusion in a biomimetic PCA, despite it being more than 10 years since the in vivo human study. It is not clear why exploration of this bioactive molecule for use as a PCA has slowed down when it shows such promise. Further clinical trials are needed to move forward the research on this growth factor.

**BMPs**

Morphogens are extracellularly secreted signals governing morphogenesis and controlling craniofacial patterning. Morphogens are divided into four evolutionarily conserved protein families: BMPs, FGFs, hedgehog proteins and WNT-related proteins (Nakashima and Reddi, 2003). BMPs are a family of 22 secreted ECM-associated proteins involved in numerous functions within the human body, such as muscle development, stem cell and organ formation, bone and cartilage formation, iron metabolism and vascular biology (Brazil et al., 2015; Nakashima and Reddi, 2003). BMPs are considered part of the TGF-β family, with both acting on Smad intracellular signalling (TGF-β utilising Smad1/5/8, BMPs utilising Smad2/3) (Brazil et al., 2015; Nakashima and Reddi, 2003).

BMPs have been added to scaffolds as DNA (gene therapy) or proteins for dentineogenic pulp capping. BMPs have a short half-life and are required in high concentrations at the local site to be effective; therefore, the ability for local elevated production of BMP proteins by the patient may be advantageous and could be achieved by gene transfection (Nakashima, 1994a; Nakashima and Reddi, 2003). An example of BMP use for gene therapy can be found in the study by Yang et al. (2009), who used an adenoviral vector containing human BMP-2 transfected into DPSCs and loaded onto a sintered ceramic scaffold. In vitro and in vivo experiments demonstrated mineralised tissue formation but with an appearance more similar to bone than to dentine. To explain the formation of bone over dentine, the authors suggested that BMP-7 may be a more appropriate candidate for dentine production and that the scaffold structure and environment (at a micro and macro level) may play a role in the formation of bone over dentine from cells of dental pulp origin. Subsequently, BMP-7 carried on nanofibrous poly(L-lactic acid) scaffolds has been used successfully in vitro and in vivo to push odontoblastic differentiation and dentine-like hard tissue formation (Wang et al., 2010).

Similarly to TGF-β1, there is a wealth of literature confirming the role of BMPs in dentineogenesis and their ability to induce odontogenic differentiation (About et al., 2000b; Chen et al., 2008; Iohara et al., 2004; Suzuki et al., 2011), with BMP2 and BMP7 being the most explored. However, there are considerably fewer studies covering the use of BMPs specifically as pulp-capping agents for in vivo applications (except for animal models) and no clinical trials have been conducted on this topic. Some of the earliest work on BMPs for pulp capping was carried out by Nakashima (1994b; 1994a), who explored BMPs for pulp capping in a dog model. Briefly, across two studies, the authors explored the use of recombinant BMP-2 and BMP-4 carried on a collagen matrix.
(Nakashima, 1994a) and mixed with inactivated, demineralised dentine matrix powder (particle size 200-500 µm size) (Nakashima, 1994b). When used in conjunction with collagen, BMP-2 (2 µg) and BMP-4 (4 µg) induced osteodentine formation; however, tubular dentine was lacking and, interestingly, the unloaded collagen carrier control produced a very minimal amount of osteodentine (Nakashima, 1994a). When used in conjunction with inactive, demineralised powered dentine, 2 µg of BMP-2 and BMP-4 induced osteodentine formation towards the superficial side of the cavities and tubular dentine towards the deeper radial part (Nakashima, 1994b).

BMP-2 has been explored as a pulp-capping agent in conjunction with MTA. 1 g MTA mixed with 1 µg BMP-2 was compared to MTA alone and no difference in the quality and quantity of reparative dentine was seen between rat groups. In addition, in both groups, the reparative dentine had a bone-like morphology (Ko et al., 2010). When BMP-7 was compared to MTA as a pulp-capping agent in rats, MTA outperformed BMP-7, with a more impervious dentine bridge being formed in the MTA group and increased DSP activity. In addition, the material produced by BMP-7 resembled bone more than dentine (Andelin et al., 2003). However, BMP-7 was added to the pulp without the adjunct of a scaffold, highlighting the potential importance of the scaffold in BMP delivery (probably for timely and sustained release) and potentially structural direction in influencing tubular dentine deposition over osteodentine.

For pulp capping, BMP-7 and BSP (each delivered on a gelatine carrier) have been shown to produce more mineralised tissue than Ca(OH)₂ in a rat model (Goldberg et al., 2001). The BMP-7 group produced more tissue towards the apical and radicular areas of the pulp, whereas the BSP group produced dentine more in the coronal area. The dentine produced by the BSP group was more tubular and less porous than the one produced by the BMP-7 group (Goldberg et al., 2001). The preferential production of osteodentine in the radicular area of the pulp was also found by Six et al. (2002b) exploring BMP-7 on collagen scaffolds as pulp caps.

Rutherford et al. (1993; 1994) explored the use of BMP-7 using primate animal models. Using a powdered collagen matrix mixed with recombinant human BMP-7 (2.5 µg/mg of collagen), they compared BMP-7 to Ca(OH)₂ (Rutherford et al., 1993) and explored tertiary dentine formation at different time points (Rutherford et al., 1994). In summary, BMP-7 outperformed Ca(OH)₂, in the short term (Rutherford et al., 1993) and demonstrated 75 % tertiary dentine bridge formation at 1 month and 95 % at 4 months (Rutherford et al., 1994). Similar to other studies, the unloaded collagen carrier failed to produce a dentine bridge, with the dentine produced being a mix of tubular dentine and osteodentine.

More recent studies have attempted to discover the optimum dosage of unloaded BMP-7 to push odontogenic differentiation in culture and maintain DPSC proliferation: 50 ng/mL and 100 ng/mL were the most successful (Zhu et al., 2018).

One issue with many of these studies is that sterile, uninfamed teeth were used. This is an issue that Rutherford and Gu (2000) attempted to resolve by exploring BMP-7 delivered on collagen scaffolds to inflamed ferret pulps. The results showed no reparative dentineogenesis, possibly in relation to elevated BMP antagonistic binding proteins present in inflamed dental pulps inactivating the protein. Rutherford (2001) went on to explore whether in vivo gene transfection of BMP-7 in an adenovirus within a collagen hydrogel carrier could induce reparative dentine formation in inflamed ferret pulps and compared this to autologous fibroblasts transfected with BMP-7 ex vivo, also carried in a collagen hydrogel into the inflamed pulps. The direct transfection group did not produce reparative dentine; however, the group with pulps capped using the ex vivo transfected fibroblasts did produce good quality reparative dentine with associated odontoblasts. The authors postulated that this may be due to sustained secretion by the fibroblasts of BMP-7.

Recombinant BMP-2 is marketed commercially for bone regeneration (InductOs™, Medtronic BioPharma, Herlelen, the Netherlands) similarly to recombinant BMP-7 (Osigraft™, Olympus Biotech, Limerick, Ireland). However, both of these systems have variable success rates and little long-term clinical evidence supporting their use (Ayoub and Gillgrass, 2019; Calori et al., 2015; Chevet-Noël et al., 2020; Corinaldesi et al., 2013; Sailhan et al., 2010; Vincentelli et al., 2019). No research has been undertaken using these materials off-label for dental-pulp capping, although the systems used are similar to the experimental work carried out using recombinant BMP-2 and BMP-7 and this could be a specific area of interest moving forwards.

Blended scaffolds have also been used to successfully deliver plasmid vectors coding for BMP-7. In the study by Yang et al. (2012), chitosan/collagen scaffolds (one containing a plasmid coding for human BMP-7 and one control) were seeded with DPSCs and implanted subcutaneously in mice. They were reviewed after 4 weeks and upregulation of DSP was observed (suggesting odontoblastic differentiation) in both groups, with a significantly higher upregulation in the BMP-7 group.

In summary, BMP-2 and BMP-7 have been used with varying degrees of success as pulp-capping agents in animal studies. Although, a bone phenotype may result in hard tissue produced and this seems to occur more when the BMP is not delivered on a scaffold. This is not ideal for pulp capping as bone is more porous than dentine and can therefore be perruous, preventing a suitable pulp seal. It is not currently known what causes a bone phenotype over a dentine phenotype; the carrier, the environment, the use of proteins or DNA may all play a role and further work is needed to resolve this issue should BMPs
be pursued as a potential pulp-capping bioactive molecule. The limitation of a high concentration of BMPs required to produce dentine, the possibility of inflammation impeding their action and the short half-life of these molecules are significant hurdles. Although there is considerable literature exploring BMPs as PCAs and clinical application of these molecules has reached the commercial market for bone regeneration, dentine is not the same as bone and until the issue of bone production over dentine production is resolved and controlled BMPs may prove less suitable for PCAs than TGF-β1 and other molecules (discussed below) may show more promise.

**IGF**

The IGF system is complex, being comprised of 2 ligands (IGF-2 and IGF-2), 2 cell surface receptors, at least 6 IGFBP and multiple proteases (Catón et al., 2007). IGF-1 is covered most widely in the literature. It is a cell surface receptor tyrosine kinase that binds to IGF-1 and IGF-2 receptors to activate various downstream signalling pathways, such as AKT/protein kinase B (a signal transduction pathway) and MAPK (Teng et al., 2018). IGF-1 has been implicated in the differentiation and proliferation of DPSCs along the odontogenic and osteogenic lineages (via the MAPK pathway) (Lv et al., 2016; Nakashima, 1992). It also plays a role in tertiary dentine formation: a mouse study by Matsumura et al. (2017) showed that tertiary dentine volume was reduced following odontoblast-specific IGF-1 ablation. IGF-1 signalling is also implicated in cell stemness, including cancer cell stemness, and resistance to chemotherapy, which has raised concerns over its use (Teng et al., 2018).

Limited in vivo work has been completed to explore the use of IGF-1 as a bioactive molecule in pulp capping. In a rat study (Lovschall et al., 2001), the efficacy of IGF-1 as a potential pulp-capping bioactive molecule was proven: recombinant IGF-1 (400 ng) was loaded onto methylcellulose gels and compared to methylcellulose gels loaded with saline and Ca(OH)₂. In all the teeth examined histologically, dentine bridges covered more than 50% of the pulp; however, significantly more tertiary dentine was identified in the IGF-1-loaded group.

When looking at IGF-2 for pulp capping in a rat model, Hu et al. (1998) found only fibrous tissue after IGF-2 treatment and, by comparison, TGF-β1 proved to be more effective for pulp capping.

With little experimental animal data, IGF-1 and IGF-2 need considerably more evidence for their efficacy before considering them as a potential bioactive molecule for pulp capping. As very little work has been done on IGF-1 for pulp capping, it seems this bioactive molecule has largely been sidelined in favour of other molecules, such as TGF-β1. Concerns over carcinogenesis may be limiting the exploration of this growth factor for use as a pulp-capping agent.

**FGF-2**

There is limited literature surrounding the use of FGF-2 for pulp capping, despite FGF-2 being implicated as a potential bioactive molecule in DPSC differentiation (Nakashima, 1992) and its proven role in tertiary dentineogenesis (Hu et al., 1998) (although admittedly to a lesser extent than TGF-β1). FGF-2 is known to be a promoter of stem cell homing, stemness, proliferation and angiogenesis (Lim et al., 2017; Smith et al., 2016).

One in vivo study exploring FGF-2 role in tertiary dentineogenesis was performed by Kikuchi et al. (2007), where collagen sponges mixed with FGF-2-loaded gelatine hydrogels were implanted into the exposed upper molars of rats. This provided a controlled release of FGF-2 and was compared to pulps capped with free FGF-2 and the collagen sponge/gelatine hydrogel mixture alone. The free FGF-2 group demonstrated tertiary dentine formation only in the residual pulp, whereas with controlled release of FGF-2, the tertiary dentine formation was all over the pulpal exposure. This demonstrated that the controlled release of FGF-2 is pertinent to the formation of dentine in a pulp cap. In a later work by Ishimatsu et al. (2009), different concentrations of FGF-2 were explored as PCAs loaded in their collagen sponge/gelatine hydrogel carrier and implanted into exposed rat pulps: DPSCs and vessels invaded the scaffold and dentine was produced. A concentration of 0.5 mg/mL of FGF-2 was found to produce the largest volume of tertiary dentine (Ishimatsu et al., 2009).

FGF-2 (like many of the bioactive molecules sequestered in dentine) has been more widely explored for bone regenerative purposes and proved to be successful in animal models (e.g., Behr et al., 2012; Hong et al., 2010; Kigami et al., 2013). Therefore, it is probably only a matter of time before exploration of FGF-2 becomes more common in the field of pulp capping and the limited current evidence is very encouraging. It does seem that controlled release of this molecule is key to its efficacy in sealing the pulp, so careful consideration of the scaffold to use for transporting FGF-2 into the tissue as well as releasing it into the pulp is required.

**EGF**

EGF is part of an EGF family of ligands and was first isolated from mouse salivary glands. When bound to their high-affinity receptors, these ligands have powerful mitogenic activities. Following binding, EGF activates two major intracellular pathways that induce cell proliferation and cytoprotection (Berlanda-Acosta et al., 2009) and it is implicated in DPSC migration (Howard et al., 2010). Although important for tissue repair and regeneration, EGF is also implicated in tumour progression (Xu et al., 2017).

Very little work has been done to explore EGF’s role in dental-pulp capping – possibly (similar to...
IGF-1) due to its known links to tumour progression. Most of the research on EGF for pulp capping is over 20 years old. As an example, Hu et al. (1997) studied the effects of PDGF (5 ng/µL) and EGF (2 ng/µL) soaked onto a collagen membrane and inserted into an exposed rat incisor. They found a combination of PDGF-BB and EGF to outperform Ca(OH)₂, and the unloaded collagen membrane (Hu et al., 1997). Hu et al. (1998) went on to explore EGF, again on collagen membranes in a rat model, in comparison to other bioactive molecules (TGF-β1, PDGF-BB, IGF-2, FGF) and compared it to the unloaded collagen carrier and Ca(OH)₂. TGF-β1 was the best at producing a dentine bridge with a tubular quality and limited pulpal inflammation. However, the authors noted that the other molecules may have therapeutic utility when used in unison (Hu et al., 1998), although this requires further exploration.

The fact that other bioactive molecules have been shown to outperform EGF limits the exploration of this molecule as a sole agent in pulp capping. However, its utility as a powerful mitogen, ability to increase cell proliferation and role in cytoprotection may prove incredibly valuable in the typically inflamed environment where pulp caps are used. For these reasons it may be beneficial to consider EGF as an adjunct in PCAs, to be used with more established molecules such as TGF-β1.

**Angiogenic molecules**

**VEGF**

The role of VEGF in pulp regeneration has been widely explored for potential revascularisation of the pulp tissue (Al-Hassiny et al., 2019; Zhang et al., 2011), due to its angiogenic properties. However, little work has been done covering the use of this bioactive molecule for pulp capping. For successful dental dental-pulp capping, a hard dentine bridge is required. VEGF, when bound to its receptor, has several functions; it stimulates endothelial cell proliferation, increases blood flow, facilitates chemotaxis, and increases capillary hyperpermeability (Al-Hassiny et al., 2019; Matsushita et al., 2000). It has a comparatively short half-life (Zhang et al., 2014), is expressed throughout the DPC in both mature and immature teeth and affects mineralisation and odontoblastic differentiation in the early stages of DPSC differentiation (Aksel and Huang, 2017). In vitro, it can induce odontoblastic differentiation of DPSCs through gene transfection (Zhang et al., 2014), demonstrating its potential use as a PCA. VEGF’s short half-life means that, without gene transfection, VEGF recombinant protein will require a carrier for sustained release. A chitosan/β-glycerophosphate scaffold carrying 100 ng/mL of VEGF protein was used successfully in vitro to achieve odontoblastic differentiation of DPSCs; moreover, the use of the carrier facilitated controlled release with better mineralisation than VEGF alone (Wu et al., 2019).

Much of the work on VEGF for pulp capping has only been accomplished in the last 5 years, possibly due to dental researchers focusing solely on its angiogenic role (as implied by its name) and failing to consider the other roles this bioactive molecule may have. To date, no in vivo studies have been carried out to explore VEGF as a PCA. Its short half-life means that controlled and sustained release may be necessary to have any significant effect. Its role in odontoblastic differentiation warrants further exploration.

**PDGF**

PDGF stimulates pulp cells and pushes their differentiation into odontoblasts (Nakashima, 1992; Zhang et al., 2017b). PDGF is present in dentine matrix (Roberts-Clark and Smith, 2000) and consists of a family of 5 polypeptides (PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, PDGF-DD), with PDGF-BB being the most widely explored as it interacts with all three PDGF receptors (Zhang et al., 2017b). PDGF is known to be a powerful mitogen, with potent angiogenic effects, and it is a key mediator in wound healing and tissue regeneration (Zhang et al., 2017b). It is also known to be a powerful chemoattractive agent for mesenchymal stem cells and DPSCs (Zhang et al., 2017b). Positive synergistic effects have been noted in vitro between PDGF and TGF-β1 as well as dentine non-collagenous proteins, leading to increased cell viability and proliferation when compared to each of these factors alone (Tabatabaei and Torshabi, 2016).

PDGF-BB can stimulate tertiary dentineogenesis, although not as much as TGF-β1 (Hu et al., 1998), possibly limiting further exploration of this molecule. Similar to HGF, the multiple roles this molecule likely plays in the healing of the DPC necessitates a better understanding of its potential therapeutic role in dentistry. More in vivo work is needed to establish the role of PDGF in dentineogenesis for pulp capping, although it seems that this peptide most likely plays a
synergistic role in a biomimetic PCA, likely coupled with another molecule.

**PIGF**

**PIGF** present in dental matrix (Roberts-Clark and Smith, 2000) is thought to play a role in osteoblastic differentiation (McCoy et al., 2013) and angiogenesis (Kinnaird et al., 2004). It has not been fully explored to elucidate its role in tertiary dentineogenesis and no in vivo work has been accomplished. Because of this, it is currently very difficult to see what role PIGF may have in a biomimetic PCA and it is included in the present review only as a matter of completeness.

**Inflammatory cytokines**

**ILs**

Inflammatory cytokines are present in dentine components sequestered in pulp caps and caries. They also have a reparative role in low-grade inflammatory processes (such as those induced by dental injury), contributing to DPC repair (Tomson et al., 2017). IL-1α, IL-1β, IL-4, IL-6, IL-8 and IL-12 are sequestered in dentine, with IL-8 being the most abundantly expressed (Cooper et al., 2010).

ILs are secreted proteins, capable of binding to specific receptors, that play a role in the communication among leukocytes (Akdis et al., 2011). Although ILs are traditionally considered to be inflammatory molecules, they are present in dentine and their associated inflammatory response is widely considered an integral part of the regenerative process of dental-pulp capping (Cooper et al., 2010; Smith et al., 2012). Careful modulation and resolution of the inflammatory process is key to facilitate regeneration (Smith et al., 2012). The balance between mild inflammation, facilitating the eradication of carious bacteria and their toxins, and tissue regeneration is delicate and complex. If the inflammatory response is too strong, the tooth will lose vascularity and become necrotic; if it is too weak, deleterious stimuli will remain, leading to increased tissue damage. It is perhaps because of this refined interplay between inflammation and regeneration that ILs have not been widely explored in the literature as a potential bioactive molecule to add to a PCA. As exogenous ILs may add to and affect the balance between inflammation and regeneration, it would be better to avoid their usage as additives to PCAs until the therapeutic levels of these proteins will be better understood.

**Colony-stimulating factors (GM-CSF and G-CSF)**

GM-CSF and G-CSF are members of the colony-stimulating factor group of glycoproteins and are known to be present in the inflamed pulp (Tomson et al., 2017). They stimulate the senescence, proliferation and differentiation of haematopoietic cells (Nakashima and Iohara, 2017; Trapnell and Abe, 2006).

The secretion of GM-CSF (and osteopontin) by immunocompetent cells at the dentine-pulp junction induces local maturation of dendritic cells, thus encouraging increased activity of odontoblasts and their differentiation from pulp resident progenitors, causing speculation over the potential role of GM-CSF in odontoblastic differentiation (Saito et al., 2011). G-CSF is effective at mobilising DPSCs (Nakashima and Iohara, 2017), which is essential for the replacement of apoptosed odontoblasts at the dentine-pulp junction, necessary for tertiary dentineogenesis.

G-CSF with autologous isolated DPSCs, on a collagen scaffold, is capable of regenerating a DPC in a dog model. For this study, numerous control groups were used, although unfortunately none with G-CSF alone, making it difficult to attribute the regeneration solely to G-CSF (Iohara et al., 2013). G-CSF is also beneficial to inducing mineralisation for dentineogenesis in vitro (Takeuchi et al., 2015).

Little work has been done to explore the roles that GM-CSF and G-CSF may play in in vivo pulp capping and the potential that harnessing these bioactive molecules may have in aiding DPSC recruitment (possibly even to a suitable acellular scaffold that is capable of being colonised) and differentiation for reparative dentineogenesis. Although both molecules are currently used therapeutically to treat haematological malignancies, more in vitro and animal work is required before they can be considered suitable for human clinical trials for pulp capping. Until the potential role of these molecules in biomimeralisation is better understood, it is unlikely that they would be used as sole agents in any PCA.

**Ig**

Igs, also known as antibodies, are Y-shaped glycoproteins predominantly produced by plasma cells. IgA, IgG and IgM are believed to be sequestered in dentine (Schmalz et al., 2017) and, likely, they play a role in the defence against cariogenic bacteria (Smith et al., 2012). The role of Igs in production of a hard tissue dentine bridge is entirely speculative, with no evidential support (Smith et al., 2012), making them for their inclusion in an experimental PCA difficult. Nevertheless, their role in combatting any residual caries would prove beneficial in a PCA, if an alternative more broad-spectrum anti-microbial was not included. They are included in this review only for completeness.

**Chemotactic**

**SCF**

SCF is a chemokine as well as homing agent for progenitor-cell recruitment and can cause a significant increase in DPSC proliferation (Pan et al., 2013). Moreover, it has a potential role in the differentiation of DPSCs towards odontoblasts (Ruangsawasdi et al., 2017). SCF is known to be released from dentine during pulp capping (Tomson et al., 2017). No in vivo pulp-capping experiments have been published so far and most of the current knowledge on SCF has been gained in the last 5
years. Exploration and potential exploitation of this bioactive molecule for DPC regeneration is still very much in its infancy and without any evidence supporting its direct role in hard-tissue barrier formation, it is likely that SCF would only have a supportive role in DPC regeneration from a PCA. Due to the lack of information surrounding this molecule for dental-pulp capping, it is included in the present review only for completeness.

**Neurotrophic proteins**

Neuropeptides have been identified in dental ECM and are thought to play various roles in pain transduction (Smith et al., 2012). Neuropeptides are associated with pulp regeneration, neural differentiation and angiogenic events (Li and Wang, 2016; Smith et al., 2016; Zhang et al., 2017a) but specifically tertiary dentineogenesis and pulp capping are less widely explored. NGF, GDNF, neurotrophin 3, neurotrophin 4/5 and BDNF are known to be sequestered in the dentine, with GDNF and neurotrophin 4/5 being the most expressed (Austah et al., 2019; Tomson et al., 2017). The role these molecules may play in pulp capping is poorly understood and is an area of recent exploration (Austah et al., 2019). No in vivo work has been completed exploring the role of neurotrophic proteins as part of a pulp-capping system, although GDNF, BDNF and neurotrophin 4/5 are thought to affect DPSC migration (Xiao et al., 2018; Xiao et al., 2020). NGF has been shown to play a potential role in differentiation of odontoblasts (Arany et al., 2009; da Rosa et al., 2018a), thereby facilitating dentineogenesis; although no in vivo work has been done to confirm this result. Evidence supporting the use of neurotrophic proteins in an experimental PCA is too weak for them to be considered as a viable option. It is likely that these molecules play a role in the inflammatory pulpal response but there is no evidence that they directly assist with hard-tissue barrier formation in the pulp. With further work exploring their actions in vitro, and eventually in vivo, they may prove useful as an additive to assist in odontoblastic differentiation but it is difficult to see how they could play a role as sole agents in a PCA.

**SIBLINGs**

After collagen, SIBLINGs are the most abundant peptides in dentine. They are capable of binding to integrin receptors, facilitating cell attachment and signalling. The SIBLING family includes OPN, BSP, DMP1, DSPP and MEPE (Bleicher et al., 2015). Members of the SIBLING family are often used as markers for odontoblast differentiation, although it is important to note that their expression can overlap with odontoblasts and be associated with bone (Smith et al., 2012).

DSPP is immediately cleaved following production of hydroxyapatite crystals (da Rosa et al., 2018a). DPP is involved in mineralisation and plays a role in the initial formation of hydroxyapatite crystals (da Rosa et al., 2018a). Very few in vivo studies focused on exploring the effects of DSPP, DSP or DPP as PCAs. One of these few studies explored the use of a DSP synthetic peptide as a PCA in a dog model (Kim et al., 2009) and compared this to MTA and Ca(OH)₂. The study found more inflammation and less hard-tissue deposition in the synthetic DSP group compared to both the MTA and Ca(OH)₂ groups, which both had similar results. In a study exploring DPP crosslinked to the fibrils of a collagen scaffold (0.5 μg of DPP and 29.5 μg type I telocollagen fibrils) in a rat model, better quality reparative dentine was found in the experimental group than in the collagen alone and Ca(OH)₂ control groups (for example, a lack of tunnel defects and more complete coverage of the pulp) (Koike et al., 2014). Koike et al. (2014) also found the rate of dentine deposition to be faster in the experimental group than in the control groups. Because the DSP synthetic peptide performed so badly compared to other PCAs, it is probably not a key molecule to pursue in the design of a biomimetic PCA. However, DPP results are encouraging and it may be that out of the two molecules cleaved from DSPP, DPP is the more pertinent for tertiary dentine formation. Further work needs to be performed exploring DSPP and its products to better understand the roles they play in dentine-bridge formation and DPC repair.

BSP is expressed in tertiary dentine and, similar to DPP, is involved in the initial formation of hydroxyapatite; although, following initial production, it can also act as an inhibitor (da Rosa et al., 2018a; Smith et al., 2012). Therefore, it may be better considered as a regulator of hydroxyapatite formation. Six et al. (2002a) compared the effects of BSP and BMP-7 (both within a gelatine carrier) for pulp capping, as previously discussed. BMP-7 predominantly elicited osteodentine deposition in the coronal and radicular areas of the pulp, leading to regenerative process following pulpal damage (Abd-Elmeguid et al., 2012). Work has been performed to explore its use for endodontic perforation repair (Alsaniea et al., 2011), finding a collagen scaffold loaded with DPSCs and DMP-1 to be capable of repairing a perforation with newly deposited dentine. DMP-1 has been hypothesised to be cleaved by MMP-2 into two forms, with the C-polypeptide form influencing the differentiation of DPSCs towards odontoblasts. The same researchers went on to explore the use of this cleaved form of DMP-1 for pulp capping when loaded onto agarose beads in a rat model and finding that the cleaved DMP-1 produced a dentine bridge faster than unloaded agarose beads and of a higher quality (Chaussain et al., 2009).
near total pulpal obliteration, whereas BSP produced a more atubular dentine, filling only a third of the crown. Like many of the SIBLINGs, the role of BSP in dentineogenesis has been explored to some degree, but very few studies have been completed assessing its potential role as a PCA. The work by Six et al. (2002a) raises the possibility that BSP may be a better bioactive molecule for inclusion in a PCA than BMP-7, partially due to its more controlled mineralisation effects and, also, due to a better, more impervious, hard-tissue barrier being formed. BSP may indeed be a key component for future PCAs and, as has been shown, can outperform the more commonly considered BMP group of molecules. This warrants further investigation.

OPN is another molecule poorly researched for pulp capping; although, this may be in part due to its perceived action of inhibiting hydroxyapatite-crystal growth (da Rosa et al., 2018a). However, OPN plays an essential role in the collagen formation of tertiary dentineogenesis from new odontoblast-like cells (Saito et al., 2016). Although inhibition of hydroxyapatite propagation may seem like the opposite effect to what is required for a PCA, careful and controlled moderation of dentine is essential for a successful clinical outcome – some PCAs [such as MTA (Agamy et al., 2004)] can cause pulpal obliteration from excessive dentine deposition, demonstrating a lack of hydroxyapatite inhibition. Further in vitro work is required to better understand the role OPN may play in tertiary dentineogenesis prior to consideration of this bioactive molecule as a PCA; although, it could be argued that the inhibitory role this molecule plays could be pivotal in controlling the dentine deposited.

The hypothesised functions of MEPE within tertiary dentineogenesis are primarily those of mineralisation regulation and inhibition as well as phosphate metabolism (Bleicher et al., 2015; da Rosa et al., 2018a). Six et al. (2007) rebuke the idea that MEPE inhibits mineralisation by exploring the actions of Dentonin, a synthetic derivative of MEPE, as a PCA when loaded onto agarose beads. Dentonin had a rapid action on the initial stages of pulpal repair (cell recruitment and cell proliferation). No evidence for mineralisation inhibition was detected in their rat model. As the exact role of MEPE in tertiary dentineogenesis is poorly understood, further work is needed to better understand the potential of this bioactive molecule as a PCA, although it is possible that it plays a regulatory role similar to the other SIBLING molecules.

SLRPs
SLRPs are a family of numerous proteoglycans, which can be subdivided into five classes: extracellular, pericellular (basement membrane zone), cell surface or intracellular, canonical and non-canonical (Listik et al., 2019). Five SLRPs have been identified in dentine matrix and predentine: decorin, biglycan, fibromodulin, lumican and osteoadherin (Orsini et al., 2009).

Decorin and biglycan have several hypothesised roles in dentineogenesis: i) collagen stabilisation, ii) collagen fibrillogenesis, iii) calcium binding, iv) hydroxyapatite interaction, v) hydroxyapatite growth inhibition (Orsini et al., 2009). Specifically, decorin and biglycan are believed to play a role in the organisation of the collagen matrix during dentineogenesis, to regulate other molecules such as TGF-β1, to influence cell cycle progression and calcium binding (Baker et al., 2009; Embry et al., 2001). Fibromodulin, osteoadherin and lumican are believed to play roles in mineralisation of dental tissues (Orsini et al., 2009). Fibromodulin may also play a role in the fibrillogenesis of collagen in predentine (Goldberg et al., 2006). Fragmented SLRPs are also thought to potentially influence signalling to odontoblasts in tertiary dentine deposition (Stankoska et al., 2016).

To date, no experimental PCA studies have explored the use of SLRPs in in vivo models. Because their breakdown may help to signal to odontoblasts to begin dentine deposition, it may be beneficial to include fragmented versions of these proteoglycans in a PCA. However, as previous studies have shown that dentine deposition can be elicited without the inclusion of these molecules, they are not a priority for consideration. Further work on the roles of these molecules in dentineogenesis is required, including further clarification of their roles in carious and regenerative settings, before they can be considered as reasonable candidates for inclusion in a PCA.

Other
ADM
ADM is a protein cleaved and processed from preproadrenomedullin, is highly conserved across species and is part of the CGRP family (Musson et al., 2010).

ADM is thought to upregulate the expression of BMP-2, enhancing odontogenic differentiation of DPSCs (Zhu et al., 2017). This fits with the current understanding of the localisation of ADM to epithelial cells during initial dental development and, later, to mineralised secretory cells (including odontoblasts) (Musson et al., 2010). ADM has also been shown to be expressed at higher levels in carious compared to healthy extracted human teeth and to inhibit apoptosis and enhance proliferation of DPSCs in vitro (Zhu et al., 2016). ADM is thought to be involved in tertiary dentineogenesis, via p38, eliciting a process of odontoblastic differentiation and mimicking primary dentineogenesis (Simon et al., 2010); although, only in vitro work currently supports this hypothesis.

Few studies have explored the role of ADM in tertiary dentineogenesis. No human or animal studies were found in the literature exploring the use of this bioactive molecule as a PCA. Its ability to inhibit apoptosis in vitro could raise concerns over its use due to the link of immortal cells to tumour cell
A theorems. Indeed, the molecule was first identified in a pheochromocytoma (a tumour of adrenal glands) (Kitamura et al., 1993). Considering the current body of work covering ADM, it is not presently a candidate for use in a PCA, although further work eliciting the actions of this molecule in tertiary dentineogenesis may yield contradictory results.

Calcitonin
Calcitonin is a hypocalcaemic hormone. It was first explored as a pulp-capping agent in 1982 when Smith and Soni (1982) used a rat model for comparing pulp capping using Ca(OH)₂ and calcitonin and discovered that calcitonin produced a similar response in terms of dentine deposition to Ca(OH)₂. Similarly, in a dog model, Cullum and Kline (1985) found that although calcitonin was able to induce pulp-capping dentineogenesis, it did not outperform Ca(OH)₂; although, less inflammation was identified in the calcitonin group. More recently, calcitonin has also been shown to stimulate osteodentine deposition in ferrets (Kline and Yu, 2009), adding to the growing literature supporting this bioactive molecule as a potential candidate for inclusion in a biomimetic PCA. Since the early work on calcitonin, little progress has been made in exploring the best way of utilising this peptide in PCAs.

Lipids
No work has been done to date using lipids sequestered in dentine for pulp capping and these are included solely for completeness.

Lipids represent a small part of the dentine matrix (0.26-0.36 %) (Goldberg et al., 2008b). Lipids found in dentine include phosphatidyl inositol, sphingomyelin, phosphatidylycholine, phosphatidylethanolamine, phosphatidylserine, phosphatidic acid and cardiolipin (Goldberg et al., 2011). Of these, sphingomyelin is the most widely explored and experimental mouse work has demonstrated that cleaving by neutral sphingomyelinases produce ceramide and phosphocholine. This process is considered important for normal dentine mineralisation (Aubin et al., 2005; Goldberg et al., 2008b). No work has been done to date exploring whether lipids are released from dentine following application of existing PCAs (such as MTA) nor whether these lipids are present in reparative dentine or what their role may be in reparative dentine formation. For these reasons, it is difficult to define what role, if any, these molecules may play in being added to a PCA and, as such, they are not a priority for consideration for inclusion in a PCA; although, further work on their roles in dentine may be beneficial to the wider dental community.

Enamel proteins
Enamel matrix has long been known to support hard-tissue formation in dental structures and has been used for dental-pulp capping in animal models (Nakamura et al., 2002). However, without knowing the exact composition of the material, it is difficult to know or hypothesise on the roles individual molecules have on tertiary dentine deposition.

Amelogenin and ameloblastin are well known enamel proteins; however, they are also present in dentine and believed to play a role in odontoblast differentiation (Goldberg et al., 2011), supporting the potential role these molecules may play in hard-tissue formation during pulp capping.

Although amelogenin is not present in healthy, mature adult dentine, predentine or pulp, it is present in injured and carious dentine at sites of injury and in newly differentiated odontoblasts. Moreover, it is present during primary dentineogenesis (Mitsiadis et al., 2014). Leading on from this work, researchers have explored the potential role that amelogenin may have in dentine hard-tissue formation for therapeutic effects. For example, it has been explored successfully for apical closure of root canals in dogs (Mounir et al., 2018). Amelogenin exists as several different isotypes and each may have different effects on dentineogenesis. Frasheri et al. (2016) found that no mineralised tissue is produced when DPSCs are exposed to full-length amelogenin. The authors suggested that amelogenin may not act as an inducer for dentine production but as an enhancer.

Ameloblastin is thought to act as a signalling molecule in primary dentineogenesis and dental-pulp complex regeneration (Spahr et al., 2002). One study has explored recombinant ameloblastin (without a carrier) as a PCA in rats, showing that it outperformed Ca(OH)₂ (Nakamura et al., 2006). However, fibrosis was found in some of the teeth capped, which could be due either to overdosing with ameloblastin, leading to rapid regenerative activity, or to chronic inflammation caused by the recombinant protein production methods (Nakamura et al., 2006). Either way, this would need addressing and exploring further before ameloblastin can be considered as a definite candidate for a PCA.

The role that some of the enamel proteins may play in reparative dentine formation is still to be completely explored and, as such, their potential use in a PCA. The fact that both ameloblastin and amelogenin have successfully produced hard-tissue barriers in animal models places these molecules as true potential candidates to be used in a PCA, although it is important to better understand the potential dose-dependent results of ameloblastin and how the different amelogenin isotypes affect dentine deposition.

Osteocalcin and calcium-binding proteins
Osteocalcin is expressed in differentiating odontoblasts (Goldberg et al., 2011) and is often used as a marker of this process.

Osteocalcin is deposited in dentine by odontoblasts, but it is found in bone and cementum too. Although inhibition of osteocalcin is known to inhibit bone production (Ducy et al., 1996), inhibition of osteocalcin (by warfarin) in mice produces no obvious difference in the structure of dentine (Gorter de Vries et al., 1991)
and excess osteocalcin does not seem to produce any effects on dentine structure either (Bronckers et al., 1998). The purpose of osteocalcin in dentine is not fully elucidated. Ferron et al. (2008) showed that it plays a role in glucose metabolism and may, therefore, be important in facilitating dentine matrix secretion in highly metabolically active odontoblasts, although this needs further clarification.

Osteonectin (also known as SPARC) is expressed in secretory odontoblasts. Osteonectin contains a calcium-binding domain and, as such, is believed to potentially play a role indirectly in dentine formation. However, further work is needed to confirm this (Goldberg et al., 2011).

Other calcium-binding proteins include calmodulin, calbindin, annexines and nucleobindin. Nucleobindin, calbindin and some of the annexines are believed to play a role in transporting calcium into the ECM during dentine deposition (Goldberg et al., 2011).

Insufficient work has been completed on osteocalcin and the calcium-binding proteins found in dentine to fully understand what their role in dentineogenesis is, let alone specifically in reparative dentineogenesis. The fact that inhibition of osteocalcin has little to no effect on dentine production suggests that either the role of osteocalcin is too minor to affect dentine production or that other pathways compensate for the inhibition of this molecule. No work has been done on using osteocalcin or calcium-binding proteins for pulp capping and, as such, this section has been included solely for completeness.

Enzymes

MMPs are calcium-dependent, zinc-containing enzymes that are sequestered in dentine and play an integral role in development and normal tissue turnover, but also in pathological events.

The main MMPs identified in dentine are MMP-8 (a collagenase), MMP-2 and MMP-9 (gelatinases), stromelysin-1 (MMP-3 or proteoglycanase), MMP-14 (MT1-MMP, an MMP-2 activator), MMP-13 and enamelysin (MMP-20) (Chaussain et al., 2013). During carious invasion, these entrapped enzymes may be re-exposed or even activated, leading to increased demineralisation and matrix breakdown (Chaussain et al., 2013). Based upon this, MMPs may be an unusual candidate for inclusion in PCAs, however they may either play a role in releasing and activating bioactive molecules from dentine – and so have an overall therapeutic effect on dental-pulp complex regeneration (Chaussain et al., 2013) – or in activating certain molecules (Chaussain et al., 2009). Also, many studies have focused on the use of MMP inhibitors for slowing down the progression of caries (Gendron et al., 1999; Sulkala et al., 2001; Tjaderhane et al., 1999), highlighting the multi-faceted effects these molecules have in the carious tooth.

Based upon the current understanding of these molecules, it may be best to consider these molecules as complicit in carious progression, as the literature proving their role in caries (through exploring MMP inhibitors) currently outweighs the evidence that they may be beneficial to dentine regeneration. As such, it is difficult to ascertain the role these enzymes would play in any PCA.

Discussion

Most in vivo studies have explored the use of single proteins as bioactive agents within various carriers. Little has been done to explore the use of multiple synergistic bioactive molecules for pulp capping in vivo. Indeed, the synergistic effect of the different peptides may yield more tertiary dentineogenesis and better mimic the physiological conditions of tertiary dentineogenesis since bioactive molecules sequestered in dentine do not work alone but as a collaborative mixture with specific roles in cell migration and cycling and hard tissue regulation and deposition. Therefore, these molecules should be used as a finely tuned and discrete cocktail of the essential components for hard-tissue formation, without causing pulpal obliteration and facilitating an impervious seal of the pulp.

When considering what would be an ideal mix of molecules to use in a PCA, careful deliberation of the role of each molecule needs to be considered – for example, the inclusion of TGF-β1 may negate the inclusion of SIBLING molecules due to its role in DSPP release. The inclusion of molecules that encourage the migration, proliferation and differentiation of DPSCs in conjunction with a molecule that will inhibit the reparative dentinogenic process, thereby preventing pulpal obliteration, is recommended. Careful consideration of the spatio-temporal release of these molecules needs to be considered in any PCA design to ensure the correct molecules are released at the correct concentration, at the correct time, and for a suitable period. Preference should be given to molecules capable of producing a dentine hard-tissue phenotype over a bone phenotype to form a more impervious dentine bridge. Some molecules can potentiate the effects of others [for example, the role of PDGF on TGF-β1 (Tabatabaei and Torshabi, 2016)], which may help to accelerate the production of a dentine bridge and should be considered for inclusion. Until the safety of some molecules is confirmed – particularly those associated with neoplastic properties – these should not be included in a PCA.

When the pulp gets exposed to toxins from caries (for example lactic acid), it becomes inflamed. There is generally a lack of studies exploring the use of bioactive molecules for pulp capping in inflamed, in vivo, pulp environments. Some authors (such as Rutherford and Gü, 2000), have attempted to address this problem. For animal studies to be comparable to clinical work, the experimental setup needs to reflect clinical practice, including carious teeth/inflamed or
infected pulps, isolation of the tooth, suitable wound lavage, haemostasis and isolation control as well as a suitable restoration. Going forwards, it would be sensible to explore this further with any bioactive molecule considered for inclusion within a pulp cap, to ensure the efficacy of direct pulp capping within an inflamed pulp environment.

Based on the literature, the peptides with the most supporting evidence are TGF-β1, BMP-2 and BMP-7. More work is required regarding the other peptides found sequestered in dentine before they can be considered to be appropriate candidates for a PCA, with a focus on *in vivo* and clinical work. It may be necessary to compare different bioactive molecules, or even biomimetic PCAs, in the same animal models to compare their efficacy. The work by Hu *et al.* (1998) is a prominent study in this instance, where EGF, IGF, basic FGF, TGF-β1, PDGF, Ca(OH)₂, a collagen carrier control and a procedure control were compared in the same rat models. Their work demonstrated that TGF-β1 induced the best hard- and soft-tissue healing.

It is likely that as work on the biology of dentine continues, more bioactive molecules sequestered in dentine will be discovered. However, many questions on the release of bioactive molecules into dentine remain unanswered, for example:

- Are they released during standard cavity preparation?
- How long is the release sustained for?
- Are they chemically or physically bound in dentine (or both)?
- Do caries influence their release dynamics?

Understanding this may help the design of a biomimetic PCA. It is of course entirely possible that not all molecules sequestered in dentine have a role to play in dentine regeneration and may simply be entombed during the process of primary dentineogenesis. The understanding of all the molecules sequestered in dentine will help a better determination of which are pertinent to tertiary dentine production.

Although some peptides have been explored as PCAs without the use of a carrier, it would be prudent to consider a carrier as an integral part of the creation of a biomimetic PCA. Carriers can allow sustained and timely release of molecules and indeed some have been demonstrated to elicite tertiary dentineogenesis without the need for additional encapsulated factors (Njeh *et al.*, 2016). Some carriers used in the literature are commercially successful PCAs. The carrier can provide some degree of mechanical and structural support, facilitate the migration of DPSCs and affect odontogenic differentiation and mineral deposition (Wang *et al.*, 2011). Some of the carriers explored for bioactive molecules can elicite tertiary dentine bridges even when unloaded (i.e. when they are used as a control without a bioactive molecule added), as shown by Goldberg *et al.* (2001) using gelatine and Koike *et al.* (2014) using collagen. These studies raise certain questions and ideas – for example, the potential role of a carrier being an active part of the PCA rather than passively releasing and holding the bioactive components as well as the possibility that the bioactive molecules sequestered in dentine and subsequently released during cavity preparation may be sufficient for dentine bridge formation without additional exogenous molecules.

A short-term area of interest may be to explore the use of existing PCAs coupled with added bioactive molecules, as has already been explored to some extent in the literature, to verify the possibility of overcoming some of the limiting factors of commercially available PCAs. Another possibility would be to utilise existing materials used for bone regeneration in a pulp-capping environment, as many of the molecules cross over, to see what effect these may have and how these may be modified to facilitate dentine production over bone.

Comparing *in vivo* animal studies is difficult without a clear clinical model comparison. It is important for *in vivo* work to include a suitable control with which to compare pulp-capping efficacy against. Without agreeing upon a clinically standardised control for use in clinical studies, a suitable control will remain contentious. With many different PCA available commercially, it may be advantageous to compare any experimental PCA against multiple different commercially available materials acting as controls for what is currently achievable in the clinic; although experimentally this may be difficult. Indeed, numerous aspects of the management of a direct pulp cap are open to debate, such as the order of the procedures, the agent used for wound lavage, the agent used for haemostasis, the preferred restorative material and the excavation technique (Bjørndal *et al.*, 2019; Chisini *et al.*, 2015; Munir *et al.*, 2020). Without consensus upon these, agreeing upon a standardised control for animal work will be difficult.

13 years ago, the *in vivo* effects of TGF-β1 and Ca(OH)₂ in human sound premolars were compared (Kunarti, 2008). Since then, newer and more effective PCAs have become available and more widely used, which may draw into question whether this is still an avenue that should be explored. With increasing numbers of subjects requiring a functional dentition for a longer time (due to an increased life expectancy), a success rate of 71% at 6 years (Çalışkan and Güneri, 2017), as for MTA for example, may not be considered a good enough outcome for a surgical procedure in an age of burgeoning regenerative medicine. Dentistry, and specifically regenerative endodontics, could lead the field of regenerative medicine providing more predictable, reproducible and successful treatment outcomes for patients. However, dentistry is falling behind the bone and cartilage regeneration field. Harnessing the innate power of the dental pulp for regeneration may prove useful in the broader field of regenerative medicine, where creation of scaffolds designed around the body’s own physiological repair mechanisms may be beneficial. However, considerable optimisation is going to be needed.
before such a material is ready for clinical trials and commercial marketing.

**Conclusion**

As there are numerous issues with currently available PCAs, the need for improved physical characteristics and better outcomes when using PCAs is paramount. The utilisation of bioactive molecules in a PCA has the potential to facilitate a more rapid, efficient and successful pulp capping. Tailoring the correct mix of bioactive molecules with the most appropriate carrier is an area that needs more exploration *in vivo*. Not only would this potentially provide a better outcome for pulp capping, but it may also elucidate the synergistic roles of many of the sequestered molecules in dentine for tertiary dentineogenesis. To date, work has focused on the formation of a dentine bridge, with less work on the regulation and inhibition of this process once successfully completed – which needs consideration to prevent pulp obliteration, for example, through inclusion of molecules such as SLRPs and SIBLINGs. Successful design of a PCA incorporating a suitable bioactive molecule with a suitable scaffold would allow the pulp native stem cells to migrate, differentiate and successfully create a tertiary dentine bridge. Such a possible clinical outcome probably involves a mixture of certain molecules. TGFβ-1, BMP-7 and BMP-2 have the most evidential support from the literature, with regards to being potential pulp-capping bioactive molecules; although there are numerous limitations to using the BMP family of molecules and other molecules may prove to be more suitable. Considerable optimisation of the various factors and carrier is required to create the most suitable biomimetic PCA (along with exploration of their use in inflamed pulp tissue) and this is only achievable through high-quality animal and clinical trials, which are still lacking.

**References**


Goldberg M, Farges J, Lacerdapiheiro S, Six N, Jegat N, Decup F, Septier D, Carrouel F, Durand S, Chauaussinoller C (2008a) Inflammatory and


Kline LW, Yu DC (2009) Effects of calcitonin, calcitonin gene-related peptide, human recombinant bone morphogenetic protein-2, and parathyroid...


Ritter AV (2007) Direct pulp-capping performed by dental students has a success rate close to 60%. Direct capping of carious pulp exposures is significantly less successful (33%) than direct capping of mechanical pulp exposures (92%). J Evid Based Dent Pract 7: 165-166.


Web Reference


Discussion with Reviewer

Pierfrancesco Pagella: What is, according to the authors, the ideal characteristic of a pulp-capping material? What is their ideal goal concerning induction of mineralisation, resolution of the inflammatory response and neovascularisation?

Authors: Many different authors have expressed different opinions on the ‘ideal characteristics of a pulp-capping material’ and we have mentioned one such example, which we feel matches the current requirements of any new pulp-capping material. However, if we were to pick just one characteristic it would be for the material to be biocompatible and non-toxic. The ideal goal would be to control inflammation and induce mineralisation. Some inflammation is necessary for reparative dentineogenesis, so complete resolution of inflammation would not be suitable. Indeed, it could be argued that placing any material on the pulp would likely induce some degree of inflammatory response. As such, we would advocate ‘control’ of inflammation, to a level assisting regeneration rather than resolution. The induction of a dentine bridge is of paramount importance to seal the pulp. If the pulp is vital (which is the only scenario when a pulp cap is traditionally attempted), it will have patent vessels and inflammation typically leads to some degree of
neovascularisation, so neovascularisation is likely to be less of an issue for a direct pulp-capping material. **Editor’s note:** The Scientific Editor responsible for this paper was Thimios Mitsiadis.